

392

European Medicines Agency
Domenico Scarlattilaan 6,
1083 HS Amsterdam

Radboud university medical center
Radboudumc Technology Center Clinical Studies

P.O. Box 9101, 6500 HB Nijmegen
The Netherlands
Internal postal code 392
Philips van Leydenlaan 15
Radboudumc entrance west, route 392
T +31 24 366 83 33

Manager Policy, Quality and Support
mrs. J.A.H. Droste, PhD
rtcclinicalstudies@radboudumc.nl
www.radboudumc.nl

Date	Our reference	Page
30 June 2022	AN/GR	1 of 1
Your reference	Contact	
	RTC Clinical Studies	

Dutch Chamber of Commerce
trade register 80262783

Subject:

Results posting of EudraCT **2007-005789-11**; "Does atorvastatin have an acute and prolonged inhibitory effect on ischemia-reperfusion injury in humans in-vivo?"

Dear EMA,

On behalf of the Prof. dr. G.A.P.J.M. Rongen as Principal Investigator of this study, I hereby confirm that screening and inclusion of subjects in the following clinical trial protocol: "Does atorvastatin have an acute and prolonged inhibitory effect on ischemia-reperfusion injury in humans in-vivo?" with EudraCT number 2007-005789-11 (favourable opinion by the Ethics Committee on March 11th 2008), **was never started**.

The reason for this was to lack of availability of Annexin A5 (essential to measure the primary outcome of this trial).

The Declaration End of Trial Form B7 reported "Completed", but this should be "**Prematurely Ended**".

We hope this information is sufficient to finalize results posting.

With kind regards,

Arjan Nooteboom,
Research Consultant at RTC Clinical Studies
Radboudumc
rtcclinicalstudies@radboudumc.nl

cc Prof.dr. G.A.P.J.M Rongen